Outstanding measure of efficacy relative to high-risk cancers with limited treatment optionsCHICAGO, (GLOBE NEWSWIRE) -- MAIA ...

A phase 2 clinical study (NCT03974022)found that sunvozertinib (Zegfrovy) was efficacious in 2 different doses, but ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer ...

Patients with recurrent or metastatic squamous cell carcinoma (HNSCC), who had markers showing they would likely respond to ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung ...